Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1316 or placebo plus concurrent chemoradiotherapy as first-line treatment for limited-stage small cell lung cancer
CTR20202660Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jan 2021; status: active.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20202660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202660.